HB 1376 requires Maryland's Medicaid (Maryland Medical Assistance Program) and Children's Health Program to provide a review within 3 business days for transfer requests to special pediatric hospitals when requested by the hospital or referring provider. It mandates retrospective reviews if a transfer is denied as "not medically necessary," with providers reimbursed for "administrative days" (days a patient remains without transfer) during the review process. The bill directly affects special pediatric hospitals - facilities serving children under 22 or those 2+ years old with co-occurring physical/behavioral health conditions - and their referring providers. Key provisions include eliminating prior authorization requirements for transfers while establishing strict timelines and reimbursement for administrative delays during appeals. This bill updates existing Medicaid and insurance rules to streamline transfers to specialized pediatric care facilities.
This bill prohibits insurers, nonprofit health plans, and health maintenance organizations from denying emergency room coverage solely because a patient did not experience a diagnosed emergency medical condition. It requires two key studies: one to quantify hospital and post-acute care bed capacity across Maryland, and another to identify ways to improve transitions from emergency to post-acute care settings. These provisions directly affect patients receiving emergency care and healthcare providers treating them, ensuring coverage isn't denied based on diagnosis alone. The studies aim to inform data-driven recommendations for future policy improvements in emergency and post-acute care access.
SB 719 restricts the land application of sewage sludge containing per- and polyfluoroalkyl substances (PFAS) above specific concentration levels, effective after a set date. It requires monitoring for PFAS in sewage sludge and products containing it, authorizes stricter pretreatment rules for industrial users discharging PFAS, and allows local jurisdictions to set fees for such discharges. The bill directly affects sewage sludge generators (like wastewater treatment facilities), industrial users, and local regulators by mandating new PFAS testing, usage limits, and fee structures. It amends Maryland’s environmental code to establish these requirements without changing existing land application rules for sludge below the new PFAS thresholds.
HB 1015 (Ralph's Act) ensures continuity of developmental disability services for individuals who recently moved to Maryland after losing their primary caregiver in another state. It directly affects people who received home- and community-based waiver services in another state for the past 10 years and relocated to live with immediate family following the death or incapacitation of their former caretaker. The bill requires the Maryland Department of Health to create an expedited 30-day process to determine eligibility, allows pre-residency eligibility assessments, and ensures those approved receive services through priority categories matching their prior state's support. This policy change prevents service disruptions during relocation transitions.
HB 772 establishes a workgroup within Maryland's Health Care Commission to develop fairer reimbursement methods for certified community behavioral health clinics and outpatient mental health centers. The workgroup will study current costs, staffing models, and federal requirements to create transparent, cost-based payment systems, comparing approaches used in other states. It must submit an interim report by December 2026 and a final report by October 2027 with specific recommendations, implementation options, and fiscal estimates. The bill does not require immediate rate changes or new funding, but rather sets a process for future policy decisions based on the workgroup's findings.
HB 1533 (the Crown and Care Act) bans 12 specific harmful ingredients - including certain phthalates, formaldehyde, mercury, and PFAS chemicals - from cosmetic products sold in Maryland. It directly affects cosmetic manufacturers, retailers, and salons by prohibiting the sale or distribution of products containing these ingredients, with limited exceptions for unavoidable trace amounts from manufacturing processes. The bill authorizes the Maryland Department of Health to investigate complaints, inspect businesses, and enforce penalties, while allowing consumers harmed by violations to seek civil damages and attorney fees. This law aims to protect public health by reducing exposure to chemicals linked to health risks like skin irritation and potential long-term harm.
HB 1483 repeals Maryland's requirement for out-of-state clinical counselors to obtain a temporary telehealth license. It allows licensed counselors from other states to provide telehealth counseling to clients who relocated to Maryland (or returned after relocating), for up to six months, if they already had an established client-counselor relationship before the move. This exempts these counselors from Maryland's standard licensure rules during the six-month continuity period, but only for existing clients who relocated - not for new clients. The bill does not change regular licensing requirements for ongoing practice in Maryland.
SB 773 allows pharmacists in Maryland to order certain vaccinations (like flu, COVID-19, or emergency vaccines) for patients aged 3 and older without needing to administer the vaccine themselves. To qualify, pharmacists must complete 20 hours of approved training, hold current CPR certification, and complete 2 hours of continuing education on immunizations. The bill requires pharmacists to follow written vaccine-specific protocols, report all vaccinations to Maryland’s ImmuNet registry, and refer pediatric patients to primary care providers when appropriate. This policy directly affects pharmacists, patients seeking these vaccines, and healthcare coordination for immunizations. The changes take effect October 1, 2026.
SB 778 creates a new "clinical research pharmacy permit" required for pharmacies conducting clinical trials in Maryland. It allows healthcare providers to own such pharmacies under specific conditions, including requiring a licensed pharmacist to be on-site at all times and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations from being classified as "practice of medicine," removing a licensing barrier for these activities. This directly affects pharmacies seeking to operate clinical trials, healthcare providers considering ownership, and the State Board of Pharmacy (as the permit issuer).
SB 159 requires Maryland's Emergency Medical Services (EMS) providers to maintain specific equipment and supplies on ambulances, including neonatal care items, and mandates quarterly reviews of performance data like response times and service quality. It also requires counties to establish formal, accessible complaint systems for ambulance quality or conduct issues, with online and in-person filing, tracking, and quarterly reporting to the state EMS Institute. These provisions directly affect all counties and municipalities operating or contracting EMS services, as well as the Maryland Institute for EMS Systems, which coordinates the statewide standards. The bill aims to standardize ambulance equipment, improve accountability through data reviews, and enhance patient access to complaint resolution. It takes effect July 1, 2026.
